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Abstract 
 
Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates up to 2.6% of the adult 
population or higher and appreciable direct and indirect costs. As a result, a concern to health 
authorities especially given the low age of onset. Consequently, a need to treat BPD patients well and 
improve their quality of life. Pharmacotherapy includes mood stabilisers and atypical antipsychotics 
(AAPs). AAPs have different mechanisms of action and side-effects so treatment needs to be tailored. 
Asenapine in clinical trials is as effective as olanzapine with less metabolic side-effects. Chitnis and 
colleagues have shown in routine care that asenapine also reduces hospital and emergency room 
admissions making it cost neutral in BPD, which is of interest to health authorities and clinicians.      
 
Main Text 
 
Bipolar I disorders (BPD) are a chronic disorder involving one or more episodes of mania or mixed 
mood, associated with increased psychomotor activity, excessive social extroversion, decreased need 
for sleep, impulsivity, impairment in judgment, and grandiose mood. Patients may also experience 
delusions, paranoid thinking, and extreme agitation (1, 2). Published prevalence rates vary from 0.4 to 
1.6 percent up to 2.6% of the adult population (1, 3) or higher, especially if the impact of under-
diagnosis and misdiagnosis are included (2, 4, 5). As Chitnis and colleagues point out, in view of the 
high prevalence of BPD including both psychiatric and associated medical conditions including thyroid 
disease, migraine, heart disease and diabetes, overall expenditure on this condition is high (3).  Direct 
medical costs were calculated at over US$30.7billion per year in the US alone in 2009, with indirect 
costs greater than US$120billion annually (2, 3).  
 
This high prevalence and costs associated with BPD are a concern to health authorities and health 
insurance companies world-wide as they struggle with increasing pressures due to ageing 
populations and the continued launch of new high priced medicines (6, 7). Concerns are increased by 
the low median age of symptom onset at just 20 to 25 years of age (1, 3). Consequently, there is a 
recognised need to treat these patients well to improve their quality of life and reduce emergency 
room visits and in-patient care.  
 
Pharmacologic treatments for BPD include mood stabilizers, e.g. lithium, valproate, lamotrigine, and 
carbamazepine, as well as atypical antipsychotics (2). The American Psychiatric Association and 
others recommend polytherapy, e.g. lithium or valproate in conjunction with an antipsychotic, for 
patients with severe manic or mixed episodes and monotherapy, e.g. lithium, valproate, or an 
antipsychotic, for less ill patients with atypical antipsychotics  (AAPs) preferred to typical 
antipsychotics because of their improved side-effect profile (1, 8-10). However other authors have 
questioned the distinction between first generation (typical) and second generation (atypical) 
antipsychotics as there are different domains of effectiveness and safety between the different 
antipsychotics (11). For instance, the extent of extrapyramidal side-effects seen with haloperidol 
depends on the doses prescribed (11). 
 
Never-the-less, it is recognised by all healthcare professionals that the different AAPs have different 
mechanisms of action and different effectiveness and safety profiles in patients with major mental 
illness including BPD (1, 11-14). Consequently, the choice of AAP prescribed should be tailored to the 
individual, especially as there are concerns with the effectiveness of some of the current AAPs for the 
management of depressive phases of bipolar disorders (10, 13). This does not include asenapine, 
which in short-term trials has demonstrated significant superiority to placebo in treating the manic 
symptoms of BPD and, in longer term studies, showed comparable efficacy with olanzapine in treating 
manic and depressive symptoms of BPD with less impact than olanzapine on adversely affecting 
triglycerides, weight and cholesterol levels (15, 16). As a result, post-hoc analysis of two short-term 
clinical trials demonstrated asenapine as a cost-effective alternative to olanzapine in mixed episode 
BD-I patients, and may have specific advantages in this population, potentially leading to healthcare 
savings and improved outcomes (17). 
 
However healthcare professionals, especially budget holders, prefer to see the effectiveness, safety 
and costs of medicines in routine clinical care to aid decision making rather than clinical trials as there 
can be appreciable differences in patients enrolled into clinical studies versus those seen in routine 
clinical care, i.e. real life. As a result affecting the generalisability of the findings from clinical trials (7).  
This is because Phase III clinical trials are typically conducted under ideal and highly controlled 
conditions to seek high internal validity to maximise the chance of demonstrating clinical benefit (7). 
Consequently, patients in routine clinical practice may in fact be more elderly and have greater co-
morbidities than those seen in clinical trials.  
 
This is the strength of the paper by Chitnis and colleagues (3). The authors assessed the impact of 
asenapine in new users, who are part of two large healthcare claims databases in the US, on 
subsequent utilisation and health care costs (3). The size of the combined databases, including both 
commercially insured personnel and Medicare enrolees, is appreciably larger than the total number of 
patients in most European countries at approximately 30 million. In view of this, providing an 
appreciable number of patients (1403) meeting the strict entry criteria, which excluded for instance 
patients with evidence of any use of depot antipsychotics during pre- or post-index as this may 
indicate patients who have difficulties complying with oral regimes (3). As a result, providing 
robustness to the findings. 
 
Robustness in the assessment of health care resource utilisation and costs is further facilitated by the 
comprehensive datasets used and the rigorous validation process. Datasets include detailed in- and 
out-patient medical claims data, incorporating both diagnoses and procedures, provider types, place 
of service and total reimbursed costs (3). Pharmacy claims included all medication dispensed and 
their details including reimbursed amounts.  
 
Encouragingly the authors found that healthcare resources decreased following asenapine. Hospital 
admissions, emergency room visits, outpatient hospital visLWVDQGSK\VLFLDQV¶RIILFHYLVLWVZHUHDOO
down (all p<0.05) (3). In addition, the findings were similar among patients with and without evidence 
of AAPs during the pre-index period. Whilst pharmacy costs increased by on average by US$839 per 
person during the post-index period, this was offset by a corresponding reduction of US$1806 in the 
cost of in-patient care, leading to an overall decrease in total BPD related costs of US$979. These are 
total costs lower rather than marginal costs in view of the methodology employed. However, these 
costs do not include indirect costs, which are substantial for this patient population (2, 3). 
 
Whilst the median age of patients with BPD in this dataset was higher at approximately 44 years 
compared with published studies of at 20 to 25 years of age (1, 3), the authors satisfactorily explain 
this difference. This included the fact that it can take up to 10 years from the time of symptom onset to 
reach a definitive diagnosis of BPD, and atypical antipsychotics may be reserved until other therapies 
such as mood stabilisers are found to be ineffective or intolerable (3). 
 
Overall these findings give confidence to all healthcare professionals that asenapine is an effective 
AAP for this group of patients, reducing inpatient services and emergency room visits, potentially 
enabling patients to function well enough to benefit from other psychosocial therapies. As mentioned 
earlier, this meets the goal of health authorities in this area of unmet need. Whilst health authorities 
typically do not get involved with directing the choice of AAP prescribed in view of the complex issues 
with managing this population and the need to individualise treatment apart from potentially looking at 
different dosage forms  (6, 18, 19), despite suggestions to the contrary (13), they should be reassured 
by these findings. This is different to the situation where there can be concerns with bias in the study 
findings as seen with for instance with long-acting injectable AAPs where a number of the published 
studies are open label and subject to significant selection and sponsor bias (20). 
 
We look forward to longer term follow-up of patients prescribed asenapine to give further confidence 
to all healthcare professionals involved with the management of patients with BPD.  
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